Liposomal Doxorubicin, Vincristine, & Dexamethasone Plus Arsenic Trioxide in Untreated Symptomatic Multiple Myeloma
Status:
Completed
Trial end date:
2008-08-01
Target enrollment:
Participant gender:
Summary
This study will assess the ability of Doxorubicin, Vincristine and Dexamethasone plus arsenic
trioxide to achieve an overall response rate of greater than 60%.